Hematologic Oncology | Specialty

Shastri Stresses the Need for Risk Stratification to Personalize Decisions in MDS

March 29th 2021

Aditi Shastri, MBBS, discusses risk stratification tools, her treatment algorithm for patients with low-risk MDS, and the role of luspatercept in this population.

Case Discussion: 68-Year-Old With R/R Follicular Lymphoma

March 29th 2021

A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.

R/R Follicular Lymphoma: Testing for EZH2

March 29th 2021

Andrew M. Evens, DO, MSc, FACP, of Rutgers Cancer Institute of New Jersey, comments on the rationale for testing for EZH2 mutations in relapsed/refractory follicular lymphoma.

Evolving Therapies in R/R DLBCL: Concluding Remarks

March 26th 2021

R/R DLBCL: A Glance at Using Novel Therapies Moving Forward

March 26th 2021

R/R DLBCL: Novel Therapies in the Pipeline

March 26th 2021

Time Frame for Development of TA-TMA

March 25th 2021

The expert panel considers the time frame of transplant-associated thrombotic microangiopathy, the subtle signs to pay attention to, and testing for proteinuria.

Criteria for Diagnosing TA-TMA

March 25th 2021

A panel of experts in hematopoietic stem cell transplantation examine their personal experience in the incidence of transplant-associated thrombotic microangiopathy in the adult and pediatric populations and the criteria used to diagnose.

Risk, Prognosis, and Nontransplant Options in Primary Myelofibrosis

March 24th 2021

Ruben A. Mesa, MD, and Srdan Verstovsek, MD, PhD, provide insight on the disease burden and prognostic scoring of primary myelofibrosis, as well as options for nontransplant candidates.

Goals in Treating Low-Risk Primary Myelofibrosis

March 24th 2021

Srdan Verstovsek, MD, PhD, shares how he assesses and typically starts treatment in patients with low-risk primary myelofibrosis, looking specifically at whether patients are symptomatic or asymptomatic. 

A Cardiologist Shares Important Insights Into the Diagnosis and Treatment of Amyloidosis

March 22nd 2021

The 3 most common types of amyloidosis––TTR mutant, TTR wild-type, and amyloid light chain––have a significant amount of cardiac involvement, making cardiologists essential players in the diagnostic workup and treatment of these patients

EZH2 Inhibition in R/R FL: Safety & Efficacy Data

March 22nd 2021

Takeaways of safety and efficacy data published on tazemetostat, an EZH2 inhibitor, to treat relapsed/refractory follicular lymphoma, and implications for using the drug in clinical practice.

Tazemetostat for R/R Follicular Lymphoma

March 22nd 2021

Drs Andrew M. Evens and Loretta J. Nastoupil remark on the recent approval of tazemetostat, an EZH2 inhibitor, as treatment for relapsed/refractory follicular lymphoma and highlight which types of patients are most appropriate to manage with this drug.

Novel Therapeutics Target Epigenetic Regulation, Immune System to Boost Activity in AML

March 20th 2021

Kira Gritsman, MD, PhD, discusses several novel agents that are under investigation to improve outcomes in poor-prognosis subsets of patients with AML, early data supporting these approaches, and the potential impact of these options on the treatment paradigm.

Dr. Herrera on Camidanlumab Tesirine in Relapsed/Refractory Hodgkin Lymphoma

March 19th 2021

Alex Herrera, MD, discusses the potential role of camidanlumab tesirine in patients with relapsed/refractory Hodgkin Lymphoma, which is currently being examined in a phase 2 clinical trial.

Dr. Martin on Selecting Among FDA-Approved BTK Inhibitors in MCL

March 19th 2021

Peter Martin, MD, discusses selecting among BTK inhibitors for the treatment of patients with mantle cell lymphoma.

Dr. Abu-Zeinah on Investigating Interferon-Alpha in Polycythemia Vera

March 19th 2021

Ghaith Abu-Zeinah, MD, discusses utilizing interferon-alpha in patients with polycythemia vera.

Treating Primary Refractory DLBCL

March 19th 2021

Bridging Therapy in R/R DLBCL

March 19th 2021

Promises and Pitfalls of MRD as a Potential Surrogate End Point in AML

March 18th 2021

Jerald Radich, MD, highlights the role minimal residual disease in acute myeloid leukemia, how different technological advanced have increased the application of MRD-based strategies, and ongoing efforts that are being made to address remaining questions.